Search

Your search keyword '"Batisse, Anne"' showing total 167 results
Start Over Author "Batisse, Anne"
167 results on '"Batisse, Anne"'

3. Les Nouveaux Produits de Synthèse (NPS) : la médiatique 3-MMC et bien d'autres.

Author

Polomeni, Pierre, Micallef, Joëlle, Eiden, Celine, Batisse, Anne, Cherki, Sabrina, Pion, Charlotte, Sicot, Romain, Gozlan, Ruth, Drougard, Corinne, and Karila, Laurent

Subjects
SYNTHETIC products, PSYCHIATRIC drugs, PUBLIC health, NONPOINT source pollution, NATURAL products
Abstract

Copyright of Médecine is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024
Full Text
View/download PDF

4. Prevalence and impact of recreational drug use in patients with acute cardiovascular events

Author

Pezel, Théo, primary, Dillinger, Jean-Guillaume, additional, Trimaille, Antonin, additional, Delmas, Clément, additional, Piliero, Nicolas, additional, Bouleti, Claire, additional, Pommier, Thibaut, additional, El Ouahidi, Amine, additional, Andrieu, Stéphane, additional, Lattuca, Benoit, additional, Rossanaly Vasram, Reza, additional, Fard, Damien, additional, Noirclerc, Nathalie, additional, Bonnet, Guillaume, additional, Goralski, Marc, additional, Elbaz, Meyer, additional, Deney, Antoine, additional, Schurtz, Guillaume, additional, Docq, Clemence, additional, Roubille, Francois, additional, Fauvel, Charles, additional, Bochaton, Thomas, additional, Aboyans, Victor, additional, Boccara, Franck, additional, Puymirat, Etienne, additional, Batisse, Anne, additional, Steg, Gabriel, additional, Vicaut, Eric, additional, and Henry, Patrick, additional

Published
2023
Full Text
View/download PDF

10. Increase of high‐risk tramadol use and harmful consequences in France from 2013 to 2018: Evidence from the triangulation of addictovigilance data

Author

Roussin, Anne, Soeiro, Thomas, Fouque, Charlotte, Jouanjus, Emilie, Frauger, Elisabeth, Fouilhé, Nathalie, Mallaret, Michel, Micallef, Joëlle, Lapeyre-Mestre, Maryse, Batisse, Anne, Chevallier, Cécile, Daveluy, Amélie, Deheul, Sylvie, Fournier-Choma, Christine, Guerlais, Marylène, Le Boisselier, Reynald, Pérault-Pochat, Marie‐christine, Roy, Sophie, Tournebize, Juliana, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Toulouse (UT), Institut de Neurosciences des Systèmes (INS), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de la Timone [CHU - APHM] (TIMONE), Equipe EQUITY, Centre d'Epidémiologie et de Recherche en santé des POPulations (CERPOP), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Service Pharmacologie Clinique [CHU Toulouse], Pôle Santé publique et médecine publique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire [Grenoble] (CHU), Addictovigilance Grenoble, Centre d'investigation clinique de Toulouse (CIC 1436), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Pôle Santé publique et médecine publique [CHU Toulouse], Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre antipoison et de toxicovigilance (Lyon) (CAPTV Lyon), Hospices Civils de Lyon (HCL), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Addictovigilance de Lille, Service de Pharmacologie Clinique [Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Addictovigilance [Caen], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), and Agence Nationale de Securite du Medicament et des Produits de Sante, ANSM

Subjects
Adult, Analgesics, Opioid, Male, Pharmacology, Cross-Sectional Studies, Substance-Related Disorders, Humans, Pain, Female, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Pharmacology (medical), France, Tramadol
Abstract

The aim of this paper is to assess recent developments in non-medical tramadol use, tramadol use disorder, illegal procurement and deaths.This study used repeated cross-sectional analysis of data collected nationwide from 2013 to 2018. Analysis was conducted through multisource monitoring of the French Addictovigilance Network of: (1) validated reports of high-risk tramadol use, (2) record systems collecting information from toxicology experts investigating analgesic-related deaths (DTA) and deaths related to substance abuse (DRAMES), and pharmacists for forged prescriptions (OSIAP), and (3) survey of drug users, with investigation of patterns of use while visiting addiction-specialised institutions (OPPIDUM).Despite a plateauing level of tramadol exposure in the French population, the proportion of tramadol reports increased 1.7-fold (187 cases in 2018, 3.2% (95% confidence interval [CI]: 2.74-3.63%), versus 1.9% (95% CI: 1.49-2.42% in 2013). Trends were similar in OSIAP: 11.9% of forged prescriptions in 2018 (95% CI: 10.56-13.45%); 1.7-fold increase; in OPPIDUM: 0.76% (95% CI: 0.55-1.02); 2.2-fold increase; and DRAMES: 3.2% of drug abuse-related deaths in 2018 (95% CI: 1.89-5.16) versus 1.7% in 2013 (95% CI: 0.65-3.84). Tramadol was the primary opioid in analgesic-related deaths in DTA (45% in 2018). Two profiles of high-risk tramadol users were identified: (1) patients treated for pain or with tramadol persistence when pain disappeared (mainly women; mean age 44 years), and (2) individuals with non-medical use for psychoactive effects (mainly men; mean age 36 years).The triangulation of the data obtained through addictovigilance monitoring evidenced a recent increase in high-risk tramadol use. These findings have a practical impact on the limitation of the maximal duration of tramadol prescriptions.

Published
2022

14. Complications liées à l’usage de substances psycho-actives chez les mineurs : cas rapportés au réseau français d’addictovigilance de 2016 à 2021

Author

Menil-Meresse, Césarine, primary, Chaouachi, Leila, additional, Daveluy, Amélie, additional, Fournier-Choma, Christine, additional, Fouilhé, Nathalie, additional, Deheul, Sylvie, additional, Chevalier, Cécile, additional, Lacroix, Clémence, additional, Tournebize, Juliana, additional, Aquizerate, Aurelie, additional, Pain, Stephanie, additional, Ponte, Camille, additional, Batisse, Anne, additional, and Peyriere, Hélène, additional

Published
2022
Full Text
View/download PDF

26. Chemsex practice in France: An update in Addictovigilance data.

Author

Batisse, Anne, Eiden, Céline, Deheul, Sylvie, Monzon, Emilie, Djezzar, Samira, and Peyrière, Hélène

Subjects
*PHARMACOEPIDEMIOLOGY, *HIV, *SUBSTANCE abuse, *HEPATITIS C
Abstract

Background: Complications related to Chemsex practice (consumption of psychoactive substances in sexual context) were first assessed by the French Addictovigilance Network in 2014. In response to the deaths reported in 2016, a new expert report was commissioned to update the complications and evolution of Chemsex‐related practices in France. Methods: Between January 2008 and August 2017, all Chemsex cases collected through the French Addictovigilance Network's epidemiological tools were analyzed. Comparison of data between two periods (before and after 2014) was performed to assess the evolution of practices. Results: Over the entire survey period, 235 Chemsex cases were identified, all of them in men, with a mean ± SD age of 39 ± 11 years, including 24 deaths (10.2%). An increase in the number of reported cases was observed from one in 2008 to 50 in the first 8 months of 2017. The main medical histories include human immunodeficiency virus (HIV; 45%) and hepatitis C (20%) infections, and substance use disorders (36%). In those 235 cases, 345 psychoactive substances were identified, mainly cathinones. Polydrug use was reported in 75% of cases. The main complications were substance use disorders (63%), acute neurological or cardiovascular intoxications (50%), various psychiatric disorders (39%), and viral and bacterial infections (18%). γ‐Butyrolactone (GBL) was present in 95% of comas. An increase in the number of deaths was observed during the survey period. Conclusion: The French Addictovigilance Network, via this pharmacoepidemiological surveillance, warns public health authorities in order to support harm reduction programs and the management of Chemsexers. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

30. Le mésusage de la cigarette électronique : une centaine de jeunes hospitalisés après avoir vapoté dans le nord-est de la France

Author

Tournebize, Juliana, primary, Gibaja, Valérie, additional, Grossenbacher, Francis, additional, Plenier, Yannick, additional, Medhioub, Yasmine, additional, Batisse, Anne, additional, Le Boisselier, Reynald, additional, Gillet, Pierre, additional, Puskarczyk, Emmanuel, additional, Gaulier, Jean-Michel, additional, and Djerada, Zoubir, additional

Published
2021
Full Text
View/download PDF

36. Ten‐year trend of opioid and nonopioid analgesic use in the French adult population

Author

Daveluy, Amélie, primary, Micallef, Joëlle, additional, Sanchez‐Pena, Paola, additional, Miremont‐Salamé, Ghada, additional, Lassalle, Régis, additional, Lacueille, Clémentine, additional, Grelaud, Angela, additional, Corand, Virginie, additional, Victorri‐Vigneau, Caroline, additional, Batisse, Anne, additional, Le Boisselier, Reynald, additional, Peyrière, Hélène, additional, Frauger, Elisabeth, additional, Lapeyre‐Mestre, Maryse, additional, and Haramburu, Françoise, additional

Published
2020
Full Text
View/download PDF

38. Benzoylfentanyl and parafluorobutyrfentanyl: Some analytical and metabolism data

Author

Richeval, Camille, primary, Baillieux, Marie, additional, Pawlak, Geoffrey, additional, Phanithavong, Mélodie, additional, Wiart, Jean-françois, additional, Humbert, Luc, additional, Batisse, Anne, additional, Lamoureux, Catherine, additional, Pfau, Grégory, additional, Nefau, Thomas, additional, Allorge, Delphine, additional, and Gaulier, Jean-Michel, additional

Published
2019
Full Text
View/download PDF

39. Adverse events of recreational cannabis use reported to the French addictovigilance network (2012–2017).

Author

Bouquet, Emilie, Pain, Stéphanie, Eiden, Céline, Jouanjus, Emilie, Richard, Nathalie, Fauconneau, Bernard, Pérault‐Pochat, Marie‐Christine, Batisse, Anne, Carton, Louise, Chevalier, Cécile, Daveluy, Amélie, Fournier‐Choma, Christine, Guerlais, Marylène, Le Boisselier, Reynald, Pochard, Liselotte, Revol, Bruno, and Tournebize, Juliana

Subjects
MARIJUANA, SINUS of valsalva, INTRACRANIAL aneurysm ruptures, NEONATAL death, RUPTURED aneurysms, INTRACRANIAL hypertension, SYNTHETIC marijuana
Abstract

Aims: To describe the adverse events (AEs) of recreational cannabis use in France between 2012 and 2017. Methods: AEs related to recreational cannabis use, alone or in combination with alcohol and/or tobacco reported to the French Addictovigilance Network were analysed (excluding cannabidiol and synthetic cannabinoids). Results: Reporting of AEs tripled between 2012 (n = 179, 6.3%, 95% confidence interval [CI] = 5.4–7.2) and 2017 (n = 562, 10.1%, 95% CI = 9.3–10.9), reaching 2217 cases. They concerned mainly men (76.4%) and users aged between 18 and 34 years (18–25: 30.9%; 26–34: 26.3%, range: 12–84 years). Cannabis was mainly inhaled (71.6%) and exposure was most often chronic (64.2%). Many types of AEs were reported: psychiatric (51.2%), neurological (15.6%), cardiac (7.8%) and gastrointestinal (7.7%), including unexpected AEs (n = 34, 1.1%). The most common effect was dependence, ranging from 10.1% (95% CI = 7.9–12.3) to 20.3% (95% CI = 17.3–23.2) over the study period. Cannabinoid hyperemesis syndrome (n = 87, 2.8%) emerged from 2015. Deaths accounted for 0.2% of all AEs (4 men and 3 women aged on average 35 years). A chronic pattern of cannabis use was reported in 4 of them (intracranial hypertension in the context of lung cancer, suicide, cerebral haematoma, neonatal death with concomitant chronic alcohol use), while in the other cases the toxicological analysis identified cannabis use (ruptured aneurysm and unknown aetiology). Conclusion: This study showed a multitude of AEs related to recreational cannabis use, including unexpected AEs and deaths. It highlights the problem of dependence and the emergence of cannabinoid hyperemesis syndrome. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

42. Intoxications lors d’une soirée entre amis après ingestion de gommes au H4-CBD

Author

Batisse, Anne, Thiebot, Pauline, Magny, Romain, Chaouachi, Leila, and Labat, Laurence

Abstract

Le « CBD bien-être » non pharmaceutique est en pleine expansion depuis 2020 avec de nombreux produits alimentaires (bonbons gélifiés, gâteaux, boissons…) disponibles sur Internet et dans le commerce. Contrairement au cannabis inhalé, les effets de l’ingestion des cannabinoïdes apparaissent après plusieurs heures, avec une variabilité individuelle liée au métabolisme, au poids et au sexe du consommateur. En 2022, le marché légal du CBD se complète avec les néocannabinoïdes hémisynthétiques (HHC ou HHCP), aux propriétés pharmacologiques inconnues. Le classement du HHC et de ses dérivés comme stupéfiant en 2023 mène actuellement à une multiplication des produits d’hémisynthèse (THC-P, H4-CBD…). L’objectif est d’alerter sur la dangerosité des denrées alimentaires issues du marché légal du CBD.

Published
2024
Full Text
View/download PDF

48. ChemSex, NPS et réduction des risques : intérêt de l’analyse de produits

Author

Batisse, Anne, primary, Chevallier, Cécile, additional, Richeval, Camille, additional, Labrouve, Vincent, additional, Martinez, Magalie, additional, Allorge, Delphine, additional, Gregoire, Muriel, additional, Batel, Philippe, additional, Marillier, Maude, additional, Nefau, Thomas, additional, Gaulier, Jean-Michel, additional, and Djezzar, Samira, additional

Published
2018
Full Text
View/download PDF

49. Antalgiques stupéfiants ordonnances sécurisées (ASOS): évolution des prescriptions des antalgiques opioïdes en fonction des indications (2007–2017)

Author

Perri-Plandé, Joelle, primary, Deschamps, Mathieu, additional, Baumevieille, Marie, additional, Gérardin, Marie, additional, Pizzoglio, Véronique, additional, Fouilhe Sam-Lai, Nathalie, additional, Pochard, Liselotte, additional, Fabre, Florence, additional, Pain, Stéphanie, additional, Batisse, Anne, additional, Serre, Anais, additional, Fournier-Choma, Christine, additional, Le Boisselier, Reynald, additional, Caous, Anne-Sylvie, additional, Kahn, Jean-Pierre, additional, Miremont-Salamé, Ghada, additional, and Daveluy, Amélie, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results